Justin Walsh
Stock Analyst at Jones Trading
(3.15)
# 2,896
Out of 5,008 analysts
37
Total ratings
50%
Success rate
2.5%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Initiates: Buy | $83 | $52.04 | +59.49% | 1 | Sep 18, 2025 | |
| LNTH Lantheus Holdings | Maintains: Buy | $109 → $84 | $51.84 | +62.04% | 10 | Sep 16, 2025 | |
| VNRX VolitionRx | Initiates: Buy | $3 | $0.65 | +361.54% | 1 | Jun 10, 2025 | |
| BLRX BioLineRx | Upgrades: Buy | $12 | $4.44 | +170.27% | 3 | May 30, 2025 | |
| CLNN Clene | Initiates: Buy | $30 | $9.07 | +230.76% | 1 | Apr 23, 2025 | |
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $98.52 | - | 1 | Apr 2, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $5.40 | +103.70% | 1 | Mar 11, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $5.94 | +203.03% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $26.44 | +58.85% | 1 | Oct 18, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $15 → $22 | $3.47 | +534.01% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.78 | +234.73% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.32 | +502.41% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $0.95 | +323.15% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $5.87 | +240.72% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360 | $33.80 | +965.09% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $1.65 | +26,566.67% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $0.82 | +9,034.09% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $41.90 | -52.26% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $1.62 | +12,245.68% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.61 | +177.01% | 1 | Jan 19, 2022 |
Praxis Precision Medicines
Sep 18, 2025
Initiates: Buy
Price Target: $83
Current: $52.04
Upside: +59.49%
Lantheus Holdings
Sep 16, 2025
Maintains: Buy
Price Target: $109 → $84
Current: $51.84
Upside: +62.04%
VolitionRx
Jun 10, 2025
Initiates: Buy
Price Target: $3
Current: $0.65
Upside: +361.54%
BioLineRx
May 30, 2025
Upgrades: Buy
Price Target: $12
Current: $4.44
Upside: +170.27%
Clene
Apr 23, 2025
Initiates: Buy
Price Target: $30
Current: $9.07
Upside: +230.76%
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $98.52
Upside: -
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $5.40
Upside: +103.70%
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $5.94
Upside: +203.03%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $26.44
Upside: +58.85%
Perspective Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $3.47
Upside: +534.01%
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $4.78
Upside: +234.73%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $3.32
Upside: +502.41%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.95
Upside: +323.15%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $5.87
Upside: +240.72%
May 16, 2023
Initiates: Buy
Price Target: $360
Current: $33.80
Upside: +965.09%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $1.65
Upside: +26,566.67%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $0.82
Upside: +9,034.09%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $41.90
Upside: -52.26%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $1.62
Upside: +12,245.68%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $3.61
Upside: +177.01%